Skip to main content

Table 2 Multivariable models for prediction of response to TNFi

From: Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?

TNFi Model Model content AUC-ROC Sens. Spec.
ADA Clinical SJC, GC use, DAS28 0.75 80 % 70 %
Clinical + miRNAs SJC, GC use, DAS28, miR-99a, miR-143 0.97 92 % 91 %
ETN Clinical CRP 0.68 67 % 75 %
Clinical + miRNAs CRP, miR-197, miR-23a 0.78 80 % 79 %
  1. Baseline clinical parameters of patients that were different between responders and non-responders (p < 0.10) were used to build a “clinical model”. In a “combined model”, the clinical parameters and miRNAs predictive for response were combined, in order to determine the additive value of miRNAs in the prediction of response. For ADA, a model containing the clinical parameters (the square root of) SJC, DAS28 and GC use was compared with a model containing these parameters and the level of circulating miRNAs associated with response to ADA, miR-99a, and miR143 (–ΔΔCrt values). For ETN, the clinical model only contained the (log-transformed) CRP and the combined model also included miR-197 and miR23. Per model AUC-ROC is shown as an indicator of the predictive ability. A useless model would score 0.5, whereas a perfect model would score 1.0. The sensitivity (proportion of positive tests among all responders) and specificity (proportion of all negative tests among all non-responders) were shown for the best cutoff value per model, according to Youden’s index.
  2. ADA adalimumab, AUC-ROC area under the receiver operating characteristic curve, CRP C-reactive protein, ETN etanercept, GC glucocorticoid, SJC swollen joint count, TNFi TNF-α-inhibitor